南极电商(002127) - 2025年5月6日投资者关系活动记录表

Group 1: Dividend and Profit Distribution - The company has distributed a total of 1.179 billion CNY in dividends since its restructuring in 2015 [1] - The proposed profit distribution plan for 2024 is to distribute 0.40 CNY (including tax) per 10 shares, totaling approximately 98.19 million CNY, pending shareholder approval [1] Group 2: Current Profitability and Business Transformation - The company is actively implementing effective business transformation, resulting in steady revenue growth and stable gross margin, despite short-term losses due to brand building and marketing investments [2] - The company has reduced brand licensing for "Nanji Ren" and is optimizing its supply chain and distribution channels, supporting partners willing to upgrade while amicably exiting those unable to progress [3] Group 3: Future Growth Points - The company operates multiple well-known brands and is focusing on enhancing product quality and brand image through a shift from open licensing to a franchise model [4][5] - The strategic focus includes "high-quality recovery + high-quality incubation" for brand services and steady growth in self-operated product sales and mobile internet marketing services [5] Group 4: Industry Performance and Competitive Position - The company has established a diversified brand matrix and a robust supply chain, maintaining good relationships with industry partners and achieving positive consumer feedback through product upgrades [5] - The company is committed to sustainable and high-quality development, aiming for steady growth through structural adjustments and professional team integration [5] Group 5: Industry Outlook - The company is optimistic about the consumption industry's future, focusing on brand image innovation and meeting diverse consumer needs through a global and strategic supply chain [6][7] - The business will continue to deepen its presence in e-commerce, social platforms, and AI advertising, enhancing internal efficiency and technology investment [7]